« back

NIHR Health Technology Assessment Programme (HTA) – Latest funding calls

  Wednesday, 04 Jan 2023 | Funding Deadline

The Health Technology Assessment (HTA) Programme funds research about the clinical and cost-effectiveness, and broader impact of healthcare treatments and tests, for those who plan, provide or receive care from NHS, and social care services. The following funding opportunities are open for application:

22/101 Management of bone metastasis and skeletal related events (SREs) in patients with advanced cancer
The HTA Programme is interested in proposals for the evaluation of interventions related to the management of bone metastasis and skeletal related events (SREs) in patients with advanced cancer. Applicants should clearly define and justify their choice of patient group, study design and outcome measures, and explain how the research will fit into the remit of the HTA Programme. Primary research, including randomised and observational studies, and evidence syntheses will be considered. Epidemiology or exploratory studies are not included within the scope of this call. We are looking for studies of interventions with a sufficient prior evidence base which show patients to positively impact the translational pathway.

22/113 Health Technology Assessment Programme researcher-led (evidence synthesis)
The HTA Programme is accepting stage one applications to this funding opportunity. Proposals should normally evaluate the clinical and cost effectiveness of a health technology. For diagnostic technologies, researchers may suggest equivalent evaluations.

22/112 Health Technology Assessment Programme researcher-led (primary research)
The HTA Programme is accepting stage one applications to this funding opportunity. Proposals should normally evaluate the clinical and cost effectiveness of a health technology. For diagnostic technologies, researchers may suggest equivalent evaluations.

22/115 NIHR James Lind Alliance Priority Setting Partnerships rolling call
The HTA Programme is accepting stage one applications to this funding opportunity. The programme recognises the importance of the research priorities identified by the James Lind Alliance (JLA) Priority Setting Partnerships (PSP) and are interested in receiving high-quality applications which address them.

22/129 Motor neurone disease highlight notice
The HTA Programme is accepting stage one applications to this funding opportunity. The NIHR is inviting research proposals that seek to develop the critical underlying infrastructure to accelerate progress in and learning from MND clinical trials. This will build on existing initiatives, networks and collaborations that capitalise on recent progress in drug development, to improve trial design and participation, validate new patient relevant outcomes and validate identified clinical biomarkers that are known to correlate to a clinical endpoint. NIHR is interested in funding studies that use innovative trial designs that have the potential to increase patient participation in clinical studies.

22/114 NIHR NICE rolling call
The HTA Programme is accepting stage one applications to this funding opportunity. The programme is interested in receiving applications to meet recommendations in research identified in NICE guidance that has been published or updated since 2015.

Deadline for proposals: 4 January 2022